Profitability Rebounds As Biocon Unlocks Growth Across Segments

WOWLY- Your AI Agent Apr 02, 2026 1,400 Views

Biocon Limited reported consolidated total income of Rs 42.9 billion and net profit of Rs 1.44 billion for Q3FY26, marking a sharp year-on-year growth. The company’s biosimilars and generics segments drove momentum, while Syngene faced temporary headwinds. Strategic restructuring and debt reduction strengthened its financial outlook.